-
1
-
-
36849065315
-
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
-
K. Rikova, A. Guo, and Q. Zeng Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
-
(2007)
Cell
, vol.131
, pp. 1190-1203
-
-
Rikova, K.1
Guo, A.2
Zeng, Q.3
-
2
-
-
84865441368
-
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
-
K.D. Davies, A.T. Le, and M.F. Theodoro Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin Cancer Res 18 2012 4570 4579
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4570-4579
-
-
Davies, K.D.1
Le, A.T.2
Theodoro, M.F.3
-
3
-
-
84863338079
-
ROS1 rearrangements define a unique molecular class of lung cancers
-
K. Bergethon, A.T. Shaw, and S.H. Ou ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
-
(2012)
J Clin Oncol
, vol.30
, pp. 863-870
-
-
Bergethon, K.1
Shaw, A.T.2
Ou, S.H.3
-
4
-
-
84865092224
-
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement
-
(abstract 7508)
-
A.T. Shaw, D.R. Camidge, J.A. Engelman, and B.J. Solomon Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement J Clin Oncol 30 suppl 2012 (abstract 7508)
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Shaw, A.T.1
Camidge, D.R.2
Engelman, J.A.3
Solomon, B.J.4
-
5
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
-
6
-
-
84857507055
-
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
-
L. Paz-Ares, F. de Marinis, and M. Dediu Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 2012 247 255
-
(2012)
Lancet Oncol
, vol.13
, pp. 247-255
-
-
Paz-Ares, L.1
De Marinis, F.2
Dediu, M.3
-
7
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
-
(2004)
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
8
-
-
64049115311
-
The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies
-
G. Scagliotti, N. Hanna, and F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies Oncologist 14 2009 253 263
-
(2009)
Oncologist
, vol.14
, pp. 253-263
-
-
Scagliotti, G.1
Hanna, N.2
Fossella, F.3
-
9
-
-
79953029071
-
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
-
D.R. Camidge, S.A. Kono, and X. Lu Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
-
(2011)
J Thorac Oncol
, vol.6
, pp. 774-780
-
-
Camidge, D.R.1
Kono, S.A.2
Lu, X.3
-
10
-
-
80052261903
-
Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer
-
J.O. Lee, T.M. Kim, and S.H. Lee Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac Oncol 6 2011 1474 1480
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1474-1480
-
-
Lee, J.O.1
Kim, T.M.2
Lee, S.H.3
-
11
-
-
84876415170
-
Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): Implications for therapy
-
(abstract 7582)
-
DR. Gandara, E. Huang, and S. Desai Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): implications for therapy J Clin Oncol 30 suppl 2012 (abstract 7582)
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Gandara, D.R.1
Huang, E.2
Desai, S.3
-
12
-
-
84876507123
-
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
-
A.T. Shaw, A.M. Varghese, and B.J. Solomon Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer Ann Oncol 24 2013 59 66
-
(2013)
Ann Oncol
, vol.24
, pp. 59-66
-
-
Shaw, A.T.1
Varghese, A.M.2
Solomon, B.J.3
|